#USA #Bethesda #Northwest Biotherapeutics #DCVax #Advent BioServices

Northwest Biotherapeutics Completes Acquisition of Advent BioServices

In a significant strategic move, Northwest Biotherapeutics, Inc. (OTCQB:NWBO), a leading biotechnology organization known for its innovative work on personalized immune therapies like DCVax®, has announced an agreement to acquire Advent BioServices Ltd. This acquisition, aimed at bolstering the company's operations, is expected to facilitate a more integrated approach to product development and manufacturing.

Overview of the Acquisition

The agreement, revealed on August 27, 2025, indicates that Advent will become a wholly owned subsidiary of Northwest Biotherapeutics following the fulfillment of specific legal conditions. This transition will allow NWBio to consolidate its operations, enhancing its capacity for growth while also leveraging synergies between the two companies. Through this acquisition, NWBio will inherit considerable assets from Advent, including crucial cryostorage facilities and a variety of other essential equipment amassed over recent years.

Additionally, 19 million NWBio securities previously issued to Advent will revert back to the company, a move that enhances its financial standing. This includes 13.5 million shares and 5.5 million options. Furthermore, the transfer will encompass important intellectual property and intangibles that Advent has accumulated, which could prove advantageous in advancing NWBio's objectives.

Strategic Rationale Behind the Acquisition

According to reports, the strategic partnership has been in the works for some time. Both NWBio and Advent have conducted extensive planning to streamline operations between the London GMP facility and the Sawston GMP facility. This merger of capabilities comes after Advent's years of dedication towards product development for the Marketing Authorization Application (MAA) concerning the DCVax®-Direct program and sets the stage for ramping up operations in Sawston.

As Linda Powers, CEO of Northwest Biotherapeutics, expressed, “This is an exciting day for the Company, entering into an agreement to bring our manufacturing and product development operations in-house.” By undertaking this merger, NWBio aims to integrate teams, enhance operational efficiency, and prepare for a substantial scale-up of capacity that could lead to broader market reach.

Financial Considerations

The financial structure of this acquisition involves payments made in installments over a two-year period, with the first payment commencing 90 days post-agreement. This payment process will include a total of £1.4 million, alongside settling the outstanding accounts payable from NWBio to Advent for services rendered under existing contracts. The calculated financial strategy positions the company favourably for potential future growth, especially with anticipated acceleration based on regulatory approvals for the DCVax®-L product.

About Northwest Biotherapeutics

Northwest Biotherapeutics is at the forefront of medical innovation, focusing on personalizing immunotherapy techniques aimed at effectively combating cancers while minimizing the toxic effects associated with traditional chemotherapy. The company's flagship product, DCVax®, is designed to empower the body’s immune system to target glioblastoma, a highly aggressive form of brain cancer. With extensive clinical testing already conducted, including a significant Phase III trial with 331 patients, the company is positioned to disrupt the current landscape of cancer treatment.

The DCVax®-Direct program further exemplifies NWBio’s commitment to tackling inoperable solid tumor cancers, having proven its efficacy in initial trial phases and gearing up for further clinical trials. With this recent acquisition, the company not only expands its operational capabilities but also reinforces its mission to develop superior cancer treatments that prioritize patient safety and efficacy.

As Northwest Biotherapeutics embarks on this promising path, stakeholders will be monitoring the developments closely as the company integrates its resources and ramps up its competitive capabilities in the biopharmaceutical industry.